Peter Carmeliet, a professor at KU-Leuven in Belgium, has been named chief scientific strategy advisor at Oncurious NV, a new oncology company founded by ThromboGenics NV and VIB, the life sciences institute in Flanders. Oncurious was set up to develop new medicines for the treatment of paediatric tumours. Research by Professor Carmeliet and colleagues in Belgium and the US led to the first preclinical data on the use of monoclonal antibodies against placental growth factor to treat medulloblastoma. One of these antibodies is Oncurious’ lead asset.
ThromboGenics announced the appointment on 26 June 2015.
Copyright 2015 Evernow Publishing Ltd